via University of Aberdeen
A new drug being trialled for treating breast cancer and diabetes has been shown to ‘melt away’ the fat inside arteries that can cause heart attacks and strokes.
Researchers from the University of Aberdeen, using pre-clinical mouse models, showed that just a single dose of the drug (Trodusquemine) completely reversed the effects of a disease that causes a host of heart problems.
Atherosclerosis is the build-up of fatty material inside the arteries.
Over time this fatty material can grow bigger until your arteries become so narrow that not enough blood can pass through.
Atherosclerosis is the condition that causes most heart attacks and strokes.
In pre-clinical tests, mice with set-in atherosclerosis, mimicking what happens in humans, had less fatty plaques in their arteries whether they had regular doses over time or just a single dose of Trodusquemine.
The drug works by stopping an enzyme called PTP1B, which is normally increased in people with obesity or diabetes and conditions involving prolonged inflammation such as sepsis, inflamed diabetic foot ulcers and allergic lung inflammation. The researchers found that it also stimulated the action of another protein (AMPK), which effectively mimics exercise and reduces chronic inflammation.
It has already been shown to be effective with diabetes and breast cancer patients but this is the first time the drug has been shown to have benefits for long-term cardiovascular disease.
The £236,000 study was funded by the British Heart Foundation.
Professor Mirela Delibegovic and Dr Dawn Thompson from the University of Aberdeen’s Institute of Medical Sciences who led the study said: “All humans have some level of atherosclerosis. As you age you start to develop these fatty streaks inside your arteries. It is a big problem for people who are overweight or have underlying cardiovascular conditions.”
“Trodusquemine has already been trialled for treatment of diabetes and breast cancer but this is the first time it has been used in models of atherosclerosis.
“These have only been tested at pre-clinical level, in mice, so far but the results were quite impressive and showed that just a single dose of this drug seemed to completely reverse the effects of arthrosclerosis.
“The next step is to test the ability of this drug to improve outcomes in human patients with developed atherosclerosis and cardiovascular disease”.
Learn more: Drug ‘melts away’ fat inside arteries
The Latest on: Atherosclerosis
- Popular Foods That May Damage Your Heart, According to Scienceon May 3, 2021 at 5:29 am
A healthy diet can help prevent heart disease, but highly-processed foods can increase your risk and damage your heart. Here's how.
- Yin-xing-tong-mai decoction attenuates atherosclerosis via activating PPARγ-LXRα-ABCA1/ABCG1 pathway.on May 2, 2021 at 10:03 pm
Atherosclerosis is now the major cause of mortality and morbidity worldwide. Formation of macrophage-derived foam cells is a hallmark of atherosclerosis, which is regulated by cholesterol uptake, ...
- Bernie Madoff cause of death revealed: hypertension, atherosclerosis, kidney failureon April 30, 2021 at 4:06 pm
Bernie Madoff, the notorious architect of the biggest investment fraud in U.S. history, died of plaque buildup in his arteries and kidney failure, according to the death certificate obtained by TMZ ...
- Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/-miceon April 27, 2021 at 7:32 am
Screening of a peptide library containing 302 peptides comprising the complete apoB100 sequence with human plasma, identified both native and malondialdehyde (MDA)-modified apoB100 peptide 210 (p210) ...
- Computer-based image analysis of atherosclerosis in the carotid arteryon April 23, 2021 at 6:51 am
Patients with atherosclerosis today usually receive preventive treatment only after a heart attack or stroke because diagnostic methods that can identify individuals and atherosclerotic plaques with ...
- Study changes traditional views on atherosclerosis, offers new avenues for treatmenton April 21, 2021 at 10:24 pm
WHO Peter Libby, MD, cardiovascular medicine specialist at Brigham and Women's Hospital and the Mallinckrodt Professor of Medicine at Harvard Medical School; author of a new review paper published in ...
- The changing landscape of atherosclerosison April 21, 2021 at 9:53 am
This Review discusses recent research that has transformed our understanding of the biology of atherosclerosis, and examines its implications for the treatment of atherosclerotic cardiovascular ...
- Review: Changing views on atherosclerosison April 21, 2021 at 8:01 am
Atherosclerosis—hardening of the arteries—is now involved in the majority of deaths worldwide, and advances in our understanding of the biology of the disease are changing traditional views ...
- Changing views on atherosclerosison April 20, 2021 at 5:00 pm
Atherosclerosis -- hardening of the arteries -- is now involved in the majority of deaths worldwide, and advances in our understanding of the biology of the disease are changing traditional views and ...
- Global Atherosclerosis Drug Industry Market Insights, Overview, Analysis and Forecast 2021-2027on April 20, 2021 at 12:17 am
Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a ...
via Google News and Bing News
